Prevalence of genital HPV infections and HPV serology in adolescent girls,prior to vaccination |
| |
| Authors: | M. Mollers M. Scherpenisse F.R.M. van der Klis A.J. King T.G.J. van Rossum E.M. van Logchem M.C. Feltkamp C.J.L.M. Meijer P.J.F. Snijders H.J. Boot H.E. de Melker |
| |
| Affiliation: | 1. Department of Epidemiology and Surveillance, National Institute of Public Health and the Environment, Bilthoven, The Netherlands;2. Laboratory for Infectious Diseases and Screening, National Institute of Public Health and the Environment, Bilthoven, The Netherlands;3. Department of Pathology, VU University Medical Centre, Amsterdam, The Netherlands;4. Medicines Evaluation Board, The Hague, The Netherlands;5. Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands;1. Universidad Católica de Valencia ‘San Vicente Mártir’, C/ Espartero, 7, 46007 Valencia, Spain;2. Vaccine Research Unit, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Avda. Catalunya 21, 46020 Valencia, Spain;3. Hospital Universitario General, Casa de la Misericordia 12, 46014 Valencia, Spain;1. Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, Germany;2. Jean-Uhmacher Institute, University of Cologne, Germany;3. Department of Otorhinolaryngology, Head and Neck Surgery, University of Mannheim, Germany;4. Department of Obstetrics and Gynecology, Evangelisches Krankenhaus Bergisch Gladbach, Germany;5. The Whiteley-Martin Research Centre, Discipline of Surgery, The University of Sydney, New South Wales, Australia;6. Department of Obstetrics and Gynecology, University of Cologne, Germany;7. Department of Otorhinolaryngology, Head and Neck Surgery, University of Giessen, Germany;1. Charles University in Prague—2nd Faculty of Medicine, V Úvalu 84, 150 06 Prague 5, Czech Republic;2. Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, 140 21 Prague 4, Czech Republic;1. Melbourne Sexual Health Centre, Alfred Health, Carlton, Melbourne, VIC, Australia;2. Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia;3. Department of Microbiology and Infectious Diseases, Royal Women''s Hospital, Parkville, Melbourne, VIC, Australia;4. Murdoch Childrens Research Institute, Parkville, Melbourne, VIC, Australia;5. Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Melbourne, VIC, Australia;6. Kirby Institute, University of New South Wales Australia, Sydney, NSW, Australia;1. Unit of Cancer Epidemiology/Belgian Cancer Centre, Scientific Institute of Public Health, J. Wytsmanstreet 14, B1050 Brussels, Belgium;2. International Centre for Reproductive Health (ICRH), Ghent University, Ghent, Belgium;3. Algemeen Medisch Labo, Sonic Healtcare, Antwerp, Belgium;4. AMBIOR, Laboratory for Cell Biology & Histology, University of Antwerp, Antwerp, Belgium;5. N. Goormachtigh Institute for Pathology, Ghent University, Ghent, Belgium;6. Department of Gynaecology & Oncology, UZ Brussel, Free University of Brussels, Brussels, Belgium;7. Department of Pathology, VUB, Brussels, Belgium;8. Department of Pathology, UZ Leuven, Leuven, Belgium;9. Department of Gynaecology and Obstetrics, UZ Leuven, Leuven, Belgium;10. Department of Microbiology and Immunology, Rega Institute, KU Leuven, Leuven, Belgium;11. Department of Pathology, ULg, Liège, Belgium;12. Institut de Pathologie et de Génétique, Charlerloi, Belgium;13. Centrum voor Medische Analyse, Herentals, Belgium;14. Pathological Anatomy, AZ Groeninge, Kortrijk, Belgium;15. Pathology Mariaziekenhuis Noord Limburg, Overpelt, Belgium;p. Vaccine & Infectious Disease Institute (VAXINFECTIO), Antwerp University, Antwerp, Belgium;q. Reproductive Health and Research, World Health Organization, Geneva, Switzerland;r. Department of Gynaecology and Obstetrics, Ghent University, Ghent, Belgium;1. Regional World Health Organization Human Papillomavirus Laboratory Network, Department of Microbiology and Infectious Diseases, The Royal Women''s Hospital, Parkville, VIC, Australia;2. Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, VIC, Australia;3. Department of Microbiology, Royal Children''s Hospital, Parkville, VIC, Australia;4. Murdoch Childrens Research Institute, Parkville, VIC, Australia;5. National HPV Vaccination Program Register, Victorian Cytology Service, East Melbourne, VIC, Australia;6. Sydney University Discipline of Paediatrics and Child Health, Children''s Hospital Westmead, Sydney, NSW, Australia;7. The Kirby Institute, University of New South Wales, Sydney, NSW, Australia;8. School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia;9. Family Planning New South Wales, Ashfield, NSW, Australia;10. Family Planning Victoria, Box Hill, VIC, Australia;11. Department of Obstetrics and Gynecology, Monash University, Clayton, VIC, Australia;12. Family Planning Western Australia, Northbridge, WA, Australia |
| |
| Abstract: | ![]()
Introduction: Monitoring the prevalence of type-specific HPV-DNA infections before and shortly after introduction of routine HPV vaccination offers the opportunity to evaluate early effects of the vaccination program. With this aim a cohort study was set up of 14- to 16-year-old girls eligible for HPV vaccination in the Netherlands. Annually, HPV-DNA and antibody status in vaginal self-samples and in serum respectively, will be studied among vaccinated (58%) and unvaccinated girls (42%). Here we present baseline data on vaginal HPV-DNA status in relation to serum antibodies. Methods: The 1800 enrolled girls filled out an internet-based questionnaire and provided a vaginal self-sample for genotype specific HPV-DNA detection using SPF10 PCR amplification and reverse line probe hybridization. Furthermore, 64% of the girls provided a blood sample for HPV antibody analysis. IgG antibodies against virus-like particles were determined for 7 HPV genotypes. Results: At baseline, type-specific HPV-DNA was detected in 4.4% (n = 79) of the 1800 girls: 2.7% (n = 49) concerned a high risk HPV type (hrHPV-DNA). The three most common types were HPV type 16, 18 and 51 (40%). Out of the hrHPV-DNA positive girls, 32% was seropositive vs. 12% in HPV-DNA negative girls (p < 0.001). Risk factors independently associated with hrHPV-DNA infection among the sexually active girls were age >15 years vs. 14–15 years (OR = 2.6 (1.2–5.9)), age of sexual debut <14 vs. above 14 years (OR = 3.0 (1.1–8.2)), total number of lifetime partners above two vs. less than two partners (OR = 3.2 (1.3–8.0)) and age of partner >17 vs. under 17 years (OR = 4.2 (1.5–13.0)). Conclusion: A low hrHPV-DNA prevalence was found in the adolescent girls. The observed vs. expected age-related increase in HPV-DNA prevalence in this cohort in the coming years (with increased sexual activity) will provide understanding of the effect of HPV vaccination. Furthermore, this cohort study will offer the opportunity to improve knowledge of antibody responses following natural infection and vaccination. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
